Aurinia Pharmaceuticals Inc.

NasdaqGM AUPH

Aurinia Pharmaceuticals Inc. Free Cash Flow Yield on December 05, 2024: 2.27%

Aurinia Pharmaceuticals Inc. Free Cash Flow Yield is 2.27% on December 05, 2024, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Aurinia Pharmaceuticals Inc. 52-week high Free Cash Flow Yield is 2.66% on November 06, 2024, which is 17.24% above the current Free Cash Flow Yield.
Aurinia Pharmaceuticals Inc. 52-week low Free Cash Flow Yield is 2.21% on December 02, 2024, which is -2.43% below the current Free Cash Flow Yield.
Aurinia Pharmaceuticals Inc. average Free Cash Flow Yield for the last 52 weeks is 2.38%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGM: AUPH

Aurinia Pharmaceuticals Inc.

CEO	Mr. Peter S. Greenleaf M.B.A.
IPO Date	Sept. 3, 2014
Location	Canada
Headquarters	4464 Markham Street
Employees	300
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Key trends

Past 5 years